Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

BACKGROUND/AIMS: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer's disease (AD) detected a treatment benefit to cognition in apolipoprotein E (APOE)-∊4-negative subjects. The current phase III stu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gold, Michael, Alderton, Claire, Zvartau-Hind, Marina, Egginton, Sally, Saunders, Ann M., Irizarry, Michael, Craft, Suzanne, Landreth, Gary, Linnamägi, Ülla, Sawchak, Sharon
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2010
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3214882/
https://ncbi.nlm.nih.gov/pubmed/20733306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000318845
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados